Safety and efficacy of AK0529 in respiratory syncytial virus-infected infant patients: A phase 2 proof-of-concept trial
Journal
Influenza and other respiratory viruses
Journal Volume
17
Journal Issue
7
Date Issued
2023-07
Author(s)
Schibler, Andreas
Huang, Yi-Chuan
Tai, Andrew
Chi, Hsin
Chieng, Chae-Hee
Wang, Jinn-Li
Goldbart, Aviv
Tang, Swee-Ping
Huang, Yhu-Chering
George, Shane
Alabaz, Derya
Bentur, Lea
Su, Siew-Choo
de Bruyne, Jessie
Karadag, Bulent
Gu, Feng
Zou, Gang
Toovey, Stephen
DeVincenzo, John P
Wu, Jim Z
Abstract
Respiratory syncytial virus (RSV) infection is a cause of substantial morbidity and mortality in young children. There is currently no effective therapy available.
Subjects
AK0529; fusion inhibitor; infants; respiratory syncytial virus (RSV); ziresovir
SDGs
Type
journal article